Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 21;13(7):850-856.
doi: 10.1039/d2md00132b. eCollection 2022 Jul 20.

Development of subtype-selective covalent ligands for the adenosine A2B receptor by tuning the reactive group

Affiliations

Development of subtype-selective covalent ligands for the adenosine A2B receptor by tuning the reactive group

Bert L H Beerkens et al. RSC Med Chem. .

Abstract

Signalling through the adenosine receptors (ARs), in particular through the adenosine A2B receptor (A2BAR), has been shown to play a role in a variety of pathological conditions, ranging from immune disorders to cancer. Covalent ligands for the A2BAR have the potential to irreversibly block the receptor, as well as inhibit all A2BAR-induced signalling pathways. This will allow a thorough investigation of the pathophysiological role of the receptor. In this study, we synthesized and evaluated a set of potential covalent ligands for the A2BAR. The ligands all contain a core scaffold consisting of a substituted xanthine, varying in type and orientation of electrophilic group (warhead). Here, we find that the right combination of these variables is necessary for a high affinity, irreversible mode of binding and selectivity towards the A2BAR. Altogether, this is the case for sulfonyl fluoride 24 (LUF7982), a covalent ligand that allows for novel ways to interrogate the A2BAR.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Scheme 1
Scheme 1. Synthesis of potential covalent ligands for the A2BAR. Reagents and conditions: (a) EDC·HCl, DIPEA, respective benzoic acid, dry DMF, rt, 2–20 h, 41–68%; (b) PPSE, 170 °C, 1–4 h, 10–53%; (c) 2 M NaOH, dioxane, 120 °C, 2–3 h, 60–84%; (d) (i) TFA, DCM, rt, 1 h; (ii) thiophosgene, 3 M HCl, rt, 2 h, 68–77%; (e) EDC·HCl, respective benzoic acid, dry DMF, rt, 1 h – 2 days, 13–54%; (f) PPSE, 150–170 °C, 2–7 h, 55–88%; (g) (i) piperidine, DMF, rt, 5 min; (ii) thiophosgene, 3 M HCl, rt, 2–4 h, 71–75%.
Fig. 1
Fig. 1. Displacement of [3H]PSB-603 from the A2BAR by (A) SO2F-substituted LUF7982; (B) OSO2F-substituted LUF7993 and (C) NCS-substituted LUF8002. Displacement measured after 0 or 4 h of pre-incubation of the respective ligand with CHO-spap membranes stably overexpressing the A2BAR. Data represent the mean ± SEM of three individual experiments performed in duplicate.
Fig. 2
Fig. 2. Wash-out assays on the adenosine A2B receptor using the N1-propyl xanthines with para-substituted warheads. CHO-spap cell membranes stably expressing the adenosine A2B receptor were pre-incubated with buffer (vehicle) or 1 μM of ligand (10 μM in case of PSB-1115), followed by a four-cycle washing treatment (4× wash) or no washing at all (control) before being exposed to [3H]PSB-603. Data represent the mean ± SEM of three individual experiments performed in duplicate. Statistics were determined using unpaired student's t tests. ns: no significant difference; ****P < 0.0001.
Fig. 3
Fig. 3. Predicted binding mode of LUF7982. Panel A: Overview of the key interactions of LUF7982 in the binding site, which include two hydrogen bonds (yellow dashed lines) with N2546.55 and π–π stacking with F173EL2, both are conserved interactions in adenosine receptor ligand recognition. The sulfonyl fluoride warhead points towards the extracellular vestibule. Panel B: Top view of the A2BAR–LUF7982 binding pocket, showing potential lysine residues involved in covalent binding (K267EL3 and K2697.32).

Similar articles

Cited by

References

    1. Fredholm B. B. IJzerman A. P. Jacobson K. A. Klotz K.-N. Linden J. Pharmacol. Rev. 2001;53:527–552. - PMC - PubMed
    1. Fredholm B. B. IJzerman A. P. Jacobson K. A. Linden J. Müller C. E. Pharmacol. Rev. 2011;63:1–34. doi: 10.1124/pr.110.003285. - DOI - PMC - PubMed
    1. Allard B. Allard D. Buisseret L. Stagg J. Nat. Rev. Clin. Oncol. 2020;17:611–629. doi: 10.1038/s41571-020-0382-2. - DOI - PubMed
    1. Chen J.-F. Eltzschig H. K. Fredholm B. B. Nat. Rev. Drug Discovery. 2013;12:265–286. doi: 10.1038/nrd3955. - DOI - PMC - PubMed
    1. Gao Z. Jacobson K. A. Int. J. Mol. Sci. 2019;20:5139. doi: 10.3390/ijms20205139. - DOI - PMC - PubMed